- Home
- CABA vs WEA Comparison
CABA vs WEA Comparison
Compare CABA & WEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CABA
- WEA
- Stock Information
- Founded
- CABA 2017
- WEA 2002
- Country
- CABA United States
- WEA United States
- Employees
- CABA N/A
- WEA N/A
- Industry
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- WEA Trusts Except Educational Religious and Charitable
- Sector
- CABA Health Care
- WEA Finance
- Exchange
- CABA Nasdaq
- WEA Nasdaq
- Market Cap
- CABA 157.4M
- WEA 129.0M
- IPO Year
- CABA 2019
- WEA N/A
- Fundamental
- Price
- CABA $1.55
- WEA $10.90
- Analyst Decision
- CABA Strong Buy
- WEA
- Analyst Count
- CABA 8
- WEA 0
- Target Price
- CABA $18.88
- WEA N/A
- AVG Volume (30 Days)
- CABA 3.0M
- WEA 46.1K
- Earning Date
- CABA 08-07-2025
- WEA 01-01-0001
- Dividend Yield
- CABA N/A
- WEA 7.87%
- EPS Growth
- CABA N/A
- WEA N/A
- EPS
- CABA N/A
- WEA N/A
- Revenue
- CABA N/A
- WEA N/A
- Revenue This Year
- CABA N/A
- WEA N/A
- Revenue Next Year
- CABA N/A
- WEA N/A
- P/E Ratio
- CABA N/A
- WEA N/A
- Revenue Growth
- CABA N/A
- WEA N/A
- 52 Week Low
- CABA $0.99
- WEA $9.60
- 52 Week High
- CABA $8.77
- WEA $11.29
- Technical
- Relative Strength Index (RSI)
- CABA 40.55
- WEA 60.49
- Support Level
- CABA $1.65
- WEA $10.69
- Resistance Level
- CABA $1.83
- WEA $10.84
- Average True Range (ATR)
- CABA 0.17
- WEA 0.10
- MACD
- CABA -0.06
- WEA 0.01
- Stochastic Oscillator
- CABA 8.33
- WEA 79.95
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.